LIVE FROM EHA 2024 - Sonrotoclax plus Zanubrutinib in R/R CLL
Failed to add items
Add to basket failed.
Add to Wish List failed.
Remove from Wish List failed.
Follow podcast failed
Unfollow podcast failed
LIVE FROM EHA 2024 - Sonrotoclax plus Zanubrutinib in R/R CLL
-
Narrated by:
-
By:
About this listen
In this episode of our podcast, recorded at the European Hematology Association (EHA) meeting in Madrid, Spain, we discuss updated results of the BGB-11417-101 trial with Dr. Stephen Opat. The BGB-11417-101 trial examined the efficacy and safety of sonrotoclax plus zanubrutinib for the treatment of R/R CLL.
Our Guest:
Dr. Stephen Opat is the director of Clinical Haematology at Monash Health, founder and chair of the Australasian Lymphoma and Related Diseases Registry and lead investigator of the Melbourne Genomics Health Alliance Lymphoma Flagship.
This podcast episode was sponsored by BeiGene Canada ULC.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com